Skip to Content

Generic Clindesse Availability

Clindesse is a brand name of clindamycin topical, approved by the FDA in the following formulation(s):

CLINDESSE (clindamycin phosphate - cream;vaginal)

  • Manufacturer: PERRIGO PHARMA INTL
    Approval date: November 30, 2004
    Strength(s): [RLD]

Has a generic version of Clindesse been approved?

No. There is currently no therapeutically equivalent version of Clindesse available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Clindesse. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Pharmaceutical preparations and methods for their administration
    Patent 5,993,856
    Issued: November 30, 1999
    Inventor(s): Ragavan; Vanaja V. & DiPiano; Gerrianne M.
    Assignee(s): FemmePharma
    Formulations which have been developed for topical or local delivery intrapelvically, intraperitoneally or directly on reproductive organs of interest administration to a region such as the female reproductive system, provide for increased comfort, increased bioavailability, rapid and relatively high blood levels in the regions to be treated in the substantial absence of systemic levels of drug which might cause side effects. These formulations consist of drug micro or nanoparticles, which may be formed of drug alone or in combination with an excipient or polymeric carrier. The excipient or polymer may be used to manipulate release rates and to increase adhesion to the affected region. The particulate formulation can be applied as a dried powder, a liquid suspension or dispersion, or as a topical ointment, creme, lotion, foam or suppository.
    Patent expiration dates:
    • November 17, 2017
      Drug product
  • Bioadhesive drug delivery system
    Patent 6,899,890
    Issued: May 31, 2005
    Inventor(s): Kirschner; Mitchell I. & Levinson; R. Saul & Riley; Thomas C. & Hermelin; Marc S.
    Assignee(s): KV Pharmaceutical Company
    The present invention relates to a novel essentially pH neutral vaginal drug delivery system suitable for modified delivery of a therapeutically active material in the vaginal cavity. The vaginal drug delivery system comprises an essentially pH neutral emulsion having globules having two phases, an internal water soluble phase and an external water-insoluble phase or film, wherein the water-soluble interior phase contains a therapeutically active drug or drugs. One novel aspect of the vaginal drug delivery system is that the internal water soluble phase comprises an acidic buffered phase.
    Patent expiration dates:
    • April 27, 2023
      Drug product
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.